|
시장보고서
상품코드
1970480
기질혈관분획(SVF) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Stromal Vascular Fraction Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
기질혈관분획(SVF) 시장 규모는 2025년 1억 9,326만 달러에서 2026-2034년 CAGR 5.54%로 성장하여 2034년에는 3억 1,398만 달러에 달할 것으로 예측됩니다.
간질혈관분획(SVF) 시장은 만성질환, 정형외과적 손상 및 미용적 문제 치료에 재생의료의 중요성이 증가함에 따라 발전하고 있습니다. 지방조직 유래 SVF는 강력한 재생능력을 가진 줄기세포, 내피세포, 성장인자가 이종 혼합된 구성이 특징입니다. 자가이식 치료에서 그 적용 범위는 정형외과, 심혈관, 피부과 영역으로 계속 확대되고 있습니다.
효소 소화, 기계적 분리, 폐쇄 시스템 처리의 기술적 진보로 SVF 추출의 수율과 안전성이 향상되었습니다. 포인트 오브 케어 기기를 통해 임상의는 단일 수술 절차 내에서 SVF를 처리하고 투여할 수 있어 워크플로우를 효율화할 수 있습니다. SVF와 비계 및 생체 재료를 결합한 연구의 진전은 조직공학의 치료 가능성을 넓혀가고 있습니다.
앞으로의 성장은 규제의 명확화와 임상적 검증을 통해 형성될 것입니다. 임상시험을 통해 장기적인 안전성과 유효성이 입증됨에 따라 주류 의료 현장으로 확대될 것으로 예측됩니다. 세포 기반 치료와 맞춤의료에 대한 투자가 증가하는 가운데, SVF는 재생의료 솔루션의 기반이 될 수 있도록 포지셔닝하고 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 기질혈관분획(SVF) 시장 : 제품별
제5장 세계의 기질혈관분획(SVF) 시장 : 방법별
제6장 세계의 기질혈관분획(SVF) 시장 : 용도별
제7장 세계의 기질혈관분획(SVF) 시장 : 최종사용자별
제8장 세계의 기질혈관분획(SVF) 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
LSH 26.03.23The Stromal Vascular Fraction Market size is expected to reach USD 313.98 Million in 2034 from USD 193.26 Million (2025) growing at a CAGR of 5.54% during 2026-2034.
The stromal vascular fraction (SVF) market is advancing as regenerative medicine gains prominence in treating chronic diseases, orthopedic injuries, and aesthetic conditions. SVF, derived from adipose tissue, contains a heterogeneous mix of stem cells, endothelial cells, and growth factors with potent regenerative capabilities. Its use in autologous therapies is expanding across orthopedic, cardiovascular, and dermatological applications.
Technological progress in enzymatic digestion, mechanical separation, and closed-system processing is enhancing the yield and safety of SVF extraction. Point-of-care devices are enabling clinicians to process and administer SVF within a single surgical procedure, streamlining workflows. Growing research on combining SVF with scaffolds and biomaterials is expanding its therapeutic potential in tissue engineering.
Future growth will be shaped by regulatory clarity and clinical validation. As clinical trials demonstrate long-term safety and efficacy, adoption is expected to expand into mainstream medical practice. With increasing investment in cell-based therapies and personalized medicine, SVF is poised to become a cornerstone in regenerative healthcare solutions.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Product
- Instruments
- Kits and Reagents
- Others (Fraction Kit, Fat Injectors, Fat Syringes & Cannulas, etc.)
By Method
- Aspiration
- Transfer
- Isolation
By Application
- Cosmetic Application
- Orthopedic Application
- Soft Tissue Application
- Others (Autoimmune Disorders, etc.)
By End-User
- Hospitals
- Specialty Clinics
- Others (Stem Cell Banks/Laboratories, etc.)
COMPANIES PROFILED
- Plus Therapeutics Inc, GE Healthcare Cytiva, formerly Biosafe GP SA, Tissue Genesis Inc, Human Med AG, InGeneron Inc, Allergan plc an AbbVie company, GID Group Inc, Bimini Health Tech, Laboratorios Fidia Farmacutica SLU, Cytori Therapeutics Inc
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL STROMAL VASCULAR FRACTION MARKET: BY PRODUCT 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Product
- 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Kits and Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Others (Fraction Kit, Fat Injectors, Fat Syringes & Cannulas, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL STROMAL VASCULAR FRACTION MARKET: BY METHOD 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Method
- 5.2. Aspiration Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Transfer Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Isolation Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL STROMAL VASCULAR FRACTION MARKET: BY APPLICATION 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Application
- 6.2. Cosmetic Application Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Orthopedic Application Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Soft Tissue Application Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.5. Others (Autoimmune Disorders, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL STROMAL VASCULAR FRACTION MARKET: BY END-USER 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast End-user
- 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Others (Stem Cell Banks/Laboratories, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL STROMAL VASCULAR FRACTION MARKET: BY REGION 2022-2034(USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Product
- 8.2.2 By Method
- 8.2.3 By Application
- 8.2.4 By End-user
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Product
- 8.3.2 By Method
- 8.3.3 By Application
- 8.3.4 By End-user
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Product
- 8.4.2 By Method
- 8.4.3 By Application
- 8.4.4 By End-user
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Product
- 8.5.2 By Method
- 8.5.3 By Application
- 8.5.4 By End-user
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Product
- 8.6.2 By Method
- 8.6.3 By Application
- 8.6.4 By End-user
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL STROMAL VASCULAR FRACTION INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 Plus Therapeutics Inc
- 10.2.2 GE Healthcare (Cytiva Formerly Biosafe GP SA)
- 10.2.4 Tissue Genesis Inc
- 10.2.5 Human Med AG
- 10.2.6 InGeneron Inc
- 10.2.7 Allergan Plc (An AbbVie Company)
- 10.2.8 GID Group Inc
- 10.2.9 Bimini Health Tech
- 10.2.10 Laboratorios Fidia FarmacAfA(C)Utica S.L.U
- 10.2.11 Cytori Therapeutics Inc
